Table 2.
Case-control analyses. Showing the 32 proteins where serum concentrations were significantly altered between cases and controls in both T-test and covariate-adjusted logistic regression, and with equal direction of fold change across the cohorts.
| SBP-S | SBP-G | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Protein | Fold change | FDRa | ORb | (95% CI)b | Pb | Fold change | FDRa | ORb | (95% CI)2 | Pb |
| Amphiregulin (AR) | 0.15 | 4.5e−02 | 1.69 | 1.04–2.82 | 4.0e−02 | 0.36 | 2.5e−04 | 6.13 | 2.40–18.03 | 3.9e−04 |
| C-C motif chemokine 3 (CCL3) | 0.11 | 3.6e−02 | 2.14 | 1.10–4.26 | 2.7e−02 | 0.33 | 7.1e−03 | 6.10 | 2.25–18.39 | 6.8e−04 |
| C-C motif chemokine 4 (CCL4) | 0.16 | 1.7e−02 | 1.86 | 1.13–3.12 | 1.7e−02 | 0.27 | 2.7e−02 | 2.60 | 1.36–5.30 | 5.7e−03 |
| C-C motif chemokine 20 (CCL20) | 0.33 | 7.1e−03 | 1.50 | 1.15–2.01 | 3.8e−03 | 0.39 | 3.3e−02 | 1.65 | 1.09–2.63 | 2.5e−02 |
| C-C motif chemokine 25 (CCL25) | 0.18 | 2.0e−02 | 2.03 | 1.28–3.26 | 3.0e−03 | 0.21 | 7.6e−02 | 2.30 | 1.20–4.64 | 1.5e−02 |
| C-X-C motif chemokine 16 (CXCL16) | 0.14 | 1.3e−04 | 6.59 | 2.37–19.40 | 4.2e−04 | 0.14 | 8.4e−03 | 8.06 | 1.66–45.79 | 1.3e−02 |
| Chitinase-3-like protein 1 (CHI3L1) | 0.25 | 1.7e−03 | 1.95 | 1.24–3.16 | 5.1e−03 | 0.33 | 2.3e−02 | 2.12 | 1.25–3.85 | 8.4e−03 |
| CUB domain-containing protein 1 (CDCP1) | 0.29 | 1.5e−05 | 4.08 | 2.09–8.36 | 6.6e−05 | 0.19 | 4.5e−02 | 4.25 | 1.56–13.11 | 7.6e−03 |
| Fms-related tyrosine kinase 3 ligand (Flt3L) | 0.24 | 2.7e−04 | 2.95 | 1.59–5.65 | 8.0e−04 | 0.14 | 8.4e−02 | 3.29 | 1.21–9.51 | 2.2e−02 |
| Folate receptor alpha (FR-alpha) | 0.19 | 2.1e−04 | 4.01 | 1.98–8.52 | 1.8e−04 | 0.16 | 2.1e−02 | 8.69 | 2.41–35.49 | 1.5e−03 |
| Galectin-3 (Gal-3) | 0.10 | 3.0e−02 | 2.79 | 1.20–6.68 | 1.9e−02 | 0.20 | 7.1e−03 | 6.33 | 1.95–23.46 | 3.5e−03 |
| Growth/differentiation factor 15 (GDF-15) | 0.34 | 1.2e−07 | 6.48 | 3.15–14.37 | 1.3e−06 | 0.25 | 6.9e−03 | 8.47 | 2.95–27.83 | 1.8e−04 |
| Interleukin-10 (IL-10) | 0.25 | 1.0e−02 | 2.26 | 1.39–3.98 | 2.4e−03 | 0.25 | 3.7e−02 | 2.47 | 1.16–5.64 | 2.5e−02 |
| Interleukin-10 receptor subunit beta (IL-10RB) | 0.14 | 1.5e−03 | 2.77 | 1.32–6.02 | 8.3e−03 | 0.19 | 8.4e−03 | 4.05 | 1.34–13.38 | 1.7e−02 |
| Interleukin-12 (IL-12) | 0.22 | 2.2e−02 | 1.73 | 1.18-2.57 | 5.5e−03 | 0.34 | 1.3e−02 | 2.14 | 1.18–4.03 | 1.5e−02 |
| Interleukin-12 subunit beta (IL-12B) | 0.22 | 4.9e−03 | 2.09 | 1.33–3.36 | 1.7e−03 | 0.31 | 1.6e−02 | 2.12 | 1.13–4.16 | 2.2e−02 |
| Interleukin-17 receptor B (IL-17RB) | −0.19 | 1.2e−02 | 0.58 | 0.36–0.92 | 2.2e−02 | -0.21 | 2.5e−02 | 0.39 | 0.16–0.89 | 3.1e−02 |
| Kallikrein-6 (KLK6) | 0.16 | 5.4e−05 | 6.34 | 2.81–15.14 | 1.6e−05 | 0.10 | 1.2e−01 | 3.80 | 1.25–12.66 | 2.3e−02 |
| Matrilysin (MMP-7) | 0.31 | 7.5e−09 | 6.28 | 3.15–13.30 | 5.4e−07 | 0.24 | 1.4e−03 | 7.04 | 2.48–22.59 | 5.0e−04 |
| Placenta growth factor (PGF) | 0.08 | 1.0e−02 | 5.60 | 1.72–19.12 | 4.9e−03 | 0.11 | 6.8e−02 | 4.35 | 1.12–18.42 | 3.8e−02 |
| Pro-adrenomedullin (AM) | 0.31 | 1.4e−07 | 5.30 | 2.68–11.02 | 3.6e−06 | 0.21 | 2.3e−02 | 2.64 | 1.14–6.46 | 2.7e−02 |
| Procathepsin L (CTSL1) | 0.13 | 1.5e−03 | 4.07 | 1.72–10.40 | 2.2e−03 | 0.23 | 4.7e−04 | 25.43 | 6.28–125.49 | 2.0e−05 |
| Prostasin (PRSS8) | 0.22 | 1.7e−06 | 5.57 | 2.51–13.06 | 4.2e−05 | 0.18 | 2.3e−02 | 6.21 | 2.00–21.16 | 2.2e−03 |
| Protransforming growth factor alpha (TGF-alpha) | 0.33 | 4.2e−05 | 2.21 | 1.44–3.50 | 4.7e−04 | 0.44 | 1.7e−04 | 3.25 | 1.67–6.76 | 8.7e−04 |
| Renin (REN) | 0.24 | 8.4e−04 | 2.60 | 1.60–4.39 | 2.0e−04 | 0.22 | 4.5e−02 | 2.87 | 1.36–6.39 | 7.2e−03 |
| Tumor necrosis factor ligand superfamily member 13B (BAFF) | 0.15 | 2.6e−03 | 2.53 | 1.30–5.06 | 7.2e−03 | 0.17 | 3.7e−03 | 6.39 | 1.51–30.24 | 1.5e−02 |
| Tumor necrosis factor receptor superfamily member 10B (TRAIL-R2) | 0.14 | 2.7e−04 | 6.61 | 2.35–19.99 | 5.3e−04 | 0.15 | 7.7e−03 | 6.84 | 1.64–32.45 | 1.1e−02 |
| Tumor necrosis factor receptor superfamily member 1A (TNF-R1) | 0.12 | 2.6e−04 | 4.88 | 1.78–14.09 | 2.6e−03 | 0.16 | 2.7e−03 | 13.09 | 2.69–73.81 | 2.2e−03 |
| Tumor necrosis factor receptor superfamily member 1B (TNF-R2) | 0.16 | 3.5e−04 | 3.37 | 1.59–7.45 | 2.0e−03 | 0.19 | 7.1e−03 | 4.41 | 1.44–14.71 | 1.2e−02 |
| Tumor necrosis factor receptor superfamily member 6 (FAS) | 0.13 | 1.3e−02 | 3.84 | 1.58–10.40 | 5.5e−03 | 0.11 | 7.6e−02 | 5.19 | 1.25–24.06 | 2.8e−02 |
| Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) | 0.13 | 9.3e−03 | 2.37 | 1.22–4.79 | 1.3e−02 | 0.21 | 1.5e−02 | 3.94 | 1.49–11.61 | 8.5e−03 |
| WAP four-disulfide core domain protein 2 (HE4) | 0.21 | 4.4e−05 | 4.74 | 2.20–10.65 | 1.1e−04 | 0.18 | 7.7e−03 | 11.90 | 3.25–50.04 | 3.5e−04 |
SBP-S/G St. Göran Bipolar Project Stockholm/Gothenburg, FDR false discovery rate, OR odds ratio, 95% CI 95% confidence interval.
aTwo-sided T-test.
bCovariate-adjusted logistic regression.